ClinicalTrials.gg
CompletedNCT05662202Updated Aug 21, 2026Results posted

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

A Phase 3 interventional study of BF-200 ALA and red light LED lamp and Vehicle and red light LED lamp in Actinic Keratoses, sponsored by Biofrontera Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Biofrontera Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Keratosis, Actinic with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Keratosis, Actinic · United States.

Enrollment
49th of 152
172 · median 73
Started
2022
with 4 others
Phase 3
44 of 165
3 open now
Registered
146th of 165
by date

Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 49th largest by enrollment of the 152 interventional ones that give a count, is one of 5 that started in 2022, is one of 44 in phase 3, and was the 146th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

16 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Keratosis, Actinic with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to test the safety, tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis (AK) on the extremities and neck/trunk.

03

Conditions studied

  • Actinic Keratoses

Browse trials for

Keywords

  • Actinic keratosis
  • Photodynamic therapy
  • 5-aminolevulinic acid
  • Photosensitizing Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness and ability of subjects to provide and sign the Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent and HIPAA form must be obtained in writing prior to starting any study procedures.
  2. 4 - 15 mild to moderate clinically confirmed AK lesions according to Olsen either on the extremities or on the neck/trunk with a diameter of ≥ 4 mm that must be present in the treatment field (defined as AK target lesions). In addition, non-target AK lesions may be present in the treatment field, including up to two severe AK lesions ≥ 4 mm. For each severe AK lesion (≥ 4 mm), a must be taken for confirmation of diagnosis. The treatment field (continuous or in several patches) totaling approx. either 80 cm², 160 cm² or 240 cm2 must be within one effective illumination area of the BF-RhodoLED® XL but may require up to three illuminations with the BF-RhodoLED®. All AK target lesions and, if applicable, severe AK lesions ≥ 4 mm located in the treatment field should be clearly distinguishable, without restrictions on the distance between lesions, and should have a minimal distance of 1 cm to the border of the treatment field.
  3. All sexes, ≥ 18 years of age.
  4. Willingness to undergo a 2 mm punch biopsy for each (up to two) severe AK lesion ≥ 4 mm, if applicable, at the screening visit.
  5. Willingness and ability to comply with study procedures, particularly willingness to receive up to 2 PDTs within approximately 12 weeks.
  6. Subjects with good general health or with clinically stable medical conditions will be permitted to be included in the study.
  7. Willingness to stop the use of moisturizers and any other non-medical topical treatments within the treatment field at least 24 h prior to the next clinical visit.
  8. Acceptance to abstain from extensive sunbathing and the use of a solarium or tanning beds during the treatment phase.
  9. For female subjects with : Negative serum pregnancy test.
  10. For female subjects with reproductive potential: Effective at screening visit and throughout the treatment phase of the study (until Visit 4 or Visit 6).

Exclusion criteria

Exclusion Criteria:

  1. Any known history of to ALA, porphyrins, or of BF-200 ALA.
  2. History of soy or peanut allergy.
  3. Sunburn or other possible confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (\< 2 cm distance) to the treatment field.
  4. (cs) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:

    1. Presence of photodermatoses or porphyria
    2. tumor or tumor with high probability of metastasis
    3. Infiltrating skin neoplasia (suspected or known)
    4. Unstable cardiovascular disease ( class III, IV)
    5. Unstable hematologic (including myelodysplastic syndrome), hepatic, renal, neurologic, or endocrine condition
    6. Unstable collagen-vascular condition
    7. Unstable gastrointestinal condition
    8. condition
    9. Presence of clinically significant inherited or acquired coagulation defect
  5. Clinical diagnosis of atopic dermatitis, Bowen´s disease (BD), basal cell carcinoma (BCC), eczema, psoriasis, rosacea, squamous cell carcinoma (SCC), other malignant or benign tumors inside or in close proximity (\< 2 cm distance) to the treatment field.
  6. Presence of strong artificial pigmentation (e.g., tattoos) or any other abnormality that may impact lesion assessment or light penetration in the treatment field.
  7. Any physical therapy such as cryotherapy, laser therapy, electrodessication, microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside or in close proximity (\< 10 cm distance) to the treatment field within 4 weeks prior to screening.
  8. Any of the topical treatments defined below within the designated periods prior to screening:

    1. Topical treatment with ALA or ALA esters (e.g., methyl aminolevulinic acid (MAL)) inside the treatment field within 3 months.
    2. Topical treatment with immunomodulatory, cytostatic, or cytotoxic drugs inside or in close proximity (\< 10 cm distance) to the treatment field within 3 months.
    3. Start of topical administration of a medication with hypericin or other drugs with phototoxic or photoallergic potential inside or in close proximity (\< 10 cm distance) to the treatment field within 4 weeks. Subjects may, however, be eligible if such medication was applied for more than 4 weeks prior to screening without evidence of an actual phototoxic/photoallergic reaction.
  9. Any use of the systemic treatments within the designated periods prior to screening:

    1. Cytostatic or cytotoxic drugs within 6 months.
    2. Immunosuppressive therapies or ALA or ALA esters (e.g., MAL) within 12 weeks.
    3. Drugs known to have major organ toxicity within 8 weeks.
    4. Interferon or glucocorticosteroids within 6 weeks.
    5. Start of intake of medication with hypericin or drugs with phototoxic or photoallergic potential within 8 weeks prior to screening. Subjects may, however, be eligible if such medication was taken in for more than 8 weeks prior to the screening visit without evidence of an actual phototoxic/photoallergic reaction.
  10. Breast feeding women.
  11. Suspicion of drug or alcohol abuse.
  12. Subjects unlikely to comply with protocol, e.g., inability to return for visits, unlikely to complete the study, or inappropriate in the opinion of the investigator.
  13. A member of study site staff or sponsor staff directly involved in the conduct of the protocol or a close relative thereof.
  14. Receipt of any drug or medical product within 8 weeks before screening or simultaneous participation in another clinical study.

Reassessment of subjects is allowed once in case exclusion criterion 3 is met and eligibility can be achieved within 4 weeks. Reassessment can be done on the day of the actual treatment.

Dosing day exclusion criteria:

At Visit 2 (baseline, PDT-1)

Subjects with sunburn or other possibly confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (\< 2 cm distance) to the treatment field. Reassessment of subjects is allowed once if the sunburn or other confounding skin conditions is/are expected to resolve within 2 weeks.

At Visit 4 (PDT-2)

Subjects with sunburn or other possibly confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (\< 2 cm distance) to the treatment field. Rescheduling of PDT-2 can be performed once at the earliest possibility after resolution, but rescheduling should not exceed 2 weeks.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    BF-200 ALA

    Topical application of BF-200 ALA containing 10% 5-ALA HCl (5-aminolevulinic acid hydrochloride). Red light photodynamic therapy (PDT)

    Combination Product: BF-200 ALA and red light LED lamp

  • Placebo comparator
    Vehicle

    Topical application of vehicle to BF-200 ALA containing no active ingredient. Red light photodynamic therapy (PDT)

    Combination Product: Vehicle and red light LED lamp

Interventions

  • Combination productBF-200 ALA and red light LED lamp

    Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT): Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing. PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.

  • Combination productVehicle and red light LED lamp

    Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT): Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing. PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.

06

What researchers measure

Primary outcomes

  1. Overall Subject Complete Response Rate

    Percentage of subjects with all AK target lesions clinically cleared after last PDT

    Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)

Secondary outcomes

  1. Overall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities

    Percentage of subjects with all AK target lesions on extremities clinically cleared after last PDT

    Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)

  2. Overall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk

    Percentage of subjects with all AK target lesions on neck/trunk clinically cleared after last PDT

    Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)

  3. Lesion Complete Response Rate

    Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after the last PDT, overall and stratified by treatment area and AK severity at baseline (according to Olsen).

    Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)

  4. Complete Response Rate for Severe Lesions

    Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen; Visit 2) after the last PDT, overall and stratified by treatment area.

    Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)

  5. Subject Complete Response Rate After PDT-1

    Percentage of subjects with all AK target lesions clinically cleared after PDT-1, overall and stratified by AK baseline parameters.

    Time frame: 12 weeks after PDT-1 (Visit 4)

  6. Lesion Complete Response Rate After PDT-1

    Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after PDT-1, overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\]).

    Time frame: 12 weeks after PDT-1 (Visit 4)

  7. Complete Response Rate for Severe Lesions After PDT-1

    Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen \[mild, moderate, severe\]; Visit 2) after PDT-1, overall and stratified by treatment area.

    Time frame: 12 weeks after PDT-1 (Visit 4)

  8. Esthetic Appearance at the End of Treatment Phase Assessed by the Investigator

    The esthetic appearance after the last PDT as assessed by the investigator according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.

    Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)

  9. Esthetic Outcome at the End of Treatment Phase Assessed by the Subject

    The esthetic outcome after the last PDT as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.

    Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)

  10. Satisfaction With PDT at the End of Treatment Phase

    Satisfaction with PDT treatment after the last PDT as assessed by the subject; overall and stratified by treatment area. Therefore, subjects were asked if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no).

    Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)

  11. Frequency and Extent of Adverse Events (AEs), AEs of Special Interest (AESIs), Serious AEs (SAEs) and Treatment-emergent AEs (TEAEs) During Treatment Phase

    Frequency and extent of AEs, AESIs, SAEs, and TEAEs, overall and stratified by demographics, skin type class (I-III and IV-VI), size of the treatment field, and treatment area. TEAEs were defined as all AEs starting with or after IMP application and within 12 weeks (+ 7 days) after the last PDT, or as related AEs (possibly, probably, or definitely related, or with missing relationship) occurring more than 12 weeks after the last PDT.

    Time frame: During entire treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)

  12. New Lesions Inside the Treatment Field During Treatment Phase

    New lesions: AK, non-melanoma skin cancer \[NMSC, including Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) or Bowen's Disease (BD)\] or melanoma

    Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)

  13. Assessment of Application Site Reactions

    Application site reactions (bleeding, burning, discharge, edema, erosion, erythema, exfoliation, hyperalgesia, induration, irritation, paraesthesia, pruritus, pustules, scabbing, or vesicles) were assessed on a 4-point scale: grade 0 = none, grade 1 = mild, grade 2 = moderate, grade 3 = severe. The worst severity across all assessment timepoints and illumination areas is presented.

    Time frame: All visits (except screening, Visit 1) throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)

  14. Application Site Pain During Illumination

    Reported by the subjects assessed on an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain); overall and stratified by size of the treatment field and treatment area. The maximum of pain score over all illuminations is shown.

    Time frame: During treatment (illumination) on treatment day for PDT-1 (Visit 2, up to 4 weeks after screening) and during treatment (illumination) on treatment day for PDT-2 (Visit 4; if applicable; 12 weeks after PDT-1)

  15. Number of Patients With Significant Changes of Vital Signs

    Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\] and changes in pulse rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)

  16. Number of Patients With Significant Changes in Safety Laboratory

    Changes in clinical chemistry, in hematology and urinalysis parameters as defined in the protocol. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)

  17. Number of Patients With Abnormal Findings in Physical Examination

    Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.

    Time frame: At screening (up to 4 weeks before treatment) and 12 weeks after the last PDT (Visit 4 or Visit 6)

Other outcomes

  1. Subject Recurrence Rate

    The percentage of subjects with all AK target lesions clinically cleared 12 weeks after the last PDT presenting with at least one recurrent lesion during follow-up, stratified by demographics, study sites, AK baseline parameters

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  2. Lesion Recurrence Rate

    The percentage of AK target lesions showing recurrence in follow-up in relation to total number of clinically cleared AK target lesions 12 weeks after last PDT; overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\])

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  3. Recurrence Rate of Severe Lesions

    The percentage of severe AK lesions (according to Olsen \[mild, moderate, severe\]) showing recurrence in follow-up in relation to total number of clinically cleared severe AK lesions 12 weeks after last PDT; overall and stratified by treatment area

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  4. Esthetic Appearance at Follow-up Visits Assessed by the Investigator

    The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  5. Esthetic Outcome at Follow-up Visits Assessed by the Subject

    The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  6. Satisfaction With PDT at Follow-up Visits

    Satisfaction with PDT treatment after the last PDT as assessed by the subject via questionnaire, 1. if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no) and 2. how they would rate the PDT treatment in comparison to other treatment modalities, if applicable (better than/ similar/ worse). The treatment modalities should be documented, if applicable); overall and stratified by treatment area

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

  7. Any SAE and Relevant AE

    Relevant AEs include AEs or conditions affecting skin health in the treatment field which may impair proper assessment of the recurrence rate of the treated AK lesions, or other clinically relevant events at the investigator's discretion as well as any SAE that has occurred since the final visit of the treatment phase (Visit 4 or Visit 6); overall and stratified by demographics and treatment area

    Time frame: Entire follow-up duration, approx. 40 weeks

  8. New Lesions Inside the Treatment Field During Follow-up

    New lesions: AK, non-melanoma skin cancer \[NMSC, including BCC, SCC or BD\] or melanoma

    Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

07

Results

Posted Aug 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneBF-200 ALAVehicle
Started13636
Completed11931
Not completed175
Withdrew: Adverse event40
Withdrew: Lost to follow-up30
Withdrew: Physician decision10
Withdrew: Withdrawal by subject42
Withdrew: Sponsor request11
Withdrew: Forbidden medication/procedure21
Withdrew: Inability to return for visits20
Withdrew: Noncompliance with study schedule01

Outcome measures

PrimaryOverall Subject Complete Response Rate

Percentage of subjects with all AK target lesions clinically cleared after last PDT

Time frame:
12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Overall Subject Complete Response Rate
ParticipantsBF-200 ALAVehicle
Overall Subject Complete Response Rate626
SecondaryOverall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities

Percentage of subjects with all AK target lesions on extremities clinically cleared after last PDT

Time frame:
12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities
ParticipantsBF-200 ALAVehicle
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities423
SecondaryOverall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk

Percentage of subjects with all AK target lesions on neck/trunk clinically cleared after last PDT

Time frame:
12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk
ParticipantsBF-200 ALAVehicle
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk203
SecondaryLesion Complete Response Rate

Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after the last PDT, overall and stratified by treatment area and AK severity at baseline (according to Olsen).

Time frame:
12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of units · Lesions
Lesion Complete Response Rate
LesionsBF-200 ALAVehicle
Overall907121
By Treatment Area: Extremities70099
By Treatment Area: Neck/Trunk20722
By AK Severity at Baseline: Mild60471
By AK Severity at Baseline: Moderate30350
SecondaryComplete Response Rate for Severe Lesions

Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen; Visit 2) after the last PDT, overall and stratified by treatment area.

Time frame:
12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of units · Severe Lesions
Complete Response Rate for Severe Lesions
Severe LesionsBF-200 ALAVehicle
Overall20
By Treatment Area: Extremities20
By Treatment Area: Neck/Trunk00
SecondarySubject Complete Response Rate After PDT-1

Percentage of subjects with all AK target lesions clinically cleared after PDT-1, overall and stratified by AK baseline parameters.

Time frame:
12 weeks after PDT-1 (Visit 4)
Reported as:
Count of participants · Participants
Subject Complete Response Rate After PDT-1
ParticipantsBF-200 ALAVehicle
Overall354
By Number of AK Target Lesions: 4 - 7172
By Number of AK Target Lesions: 8 - 11102
By Number of AK Target Lesions: 12 - 1580
By Size of Treatment Field: 80 cm²90
By Size of Treatment Field: 160 cm²173
By Size of Treatment Field: 240 cm²91
By Treatment Area: Extremities182
By Treatment Area: Neck/Trunk172
Other pre-specifiedSubject Recurrence Rate

The percentage of subjects with all AK target lesions clinically cleared 12 weeks after the last PDT presenting with at least one recurrent lesion during follow-up, stratified by demographics, study sites, AK baseline parameters

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedLesion Recurrence Rate

The percentage of AK target lesions showing recurrence in follow-up in relation to total number of clinically cleared AK target lesions 12 weeks after last PDT; overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\])

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedRecurrence Rate of Severe Lesions

The percentage of severe AK lesions (according to Olsen \[mild, moderate, severe\]) showing recurrence in follow-up in relation to total number of clinically cleared severe AK lesions 12 weeks after last PDT; overall and stratified by treatment area

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedEsthetic Appearance at Follow-up Visits Assessed by the Investigator

The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedEsthetic Outcome at Follow-up Visits Assessed by the Subject

The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedSatisfaction With PDT at Follow-up Visits

Satisfaction with PDT treatment after the last PDT as assessed by the subject via questionnaire, 1. if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no) and 2. how they would rate the PDT treatment in comparison to other treatment modalities, if applicable (better than/ similar/ worse). The treatment modalities should be documented, if applicable); overall and stratified by treatment area

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

Other pre-specifiedAny SAE and Relevant AE

Relevant AEs include AEs or conditions affecting skin health in the treatment field which may impair proper assessment of the recurrence rate of the treated AK lesions, or other clinically relevant events at the investigator's discretion as well as any SAE that has occurred since the final visit of the treatment phase (Visit 4 or Visit 6); overall and stratified by demographics and treatment area

Time frame:
Entire follow-up duration, approx. 40 weeks

Results for this outcome have not been posted.

Other pre-specifiedNew Lesions Inside the Treatment Field During Follow-up

New lesions: AK, non-melanoma skin cancer \[NMSC, including BCC, SCC or BD\] or melanoma

Time frame:
On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)

Results for this outcome have not been posted.

SecondaryLesion Complete Response Rate After PDT-1

Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after PDT-1, overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\]).

Time frame:
12 weeks after PDT-1 (Visit 4)
Reported as:
Count of units · Number of Lesions
Lesion Complete Response Rate After PDT-1
Number of LesionsBF-200 ALAVehicle
Overall78389
By Treatment Area: Extremities58474
By Treatment Area: Neck/Trunk19915
By AK Severity at Baseline: Mild52259
By AK Severity at Baseline: Moderate26130
SecondaryComplete Response Rate for Severe Lesions After PDT-1

Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen \[mild, moderate, severe\]; Visit 2) after PDT-1, overall and stratified by treatment area.

Time frame:
12 weeks after PDT-1 (Visit 4)
Reported as:
Count of units · Number of Severe Lesions
Complete Response Rate for Severe Lesions After PDT-1
Number of Severe LesionsBF-200 ALAVehicle
Overall10
By Treatment Area: Extremities10
By Treatment Area: Neck/Trunk00
SecondaryEsthetic Appearance at the End of Treatment Phase Assessed by the Investigator

The esthetic appearance after the last PDT as assessed by the investigator according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.

Time frame:
On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Esthetic Appearance at the End of Treatment Phase Assessed by the Investigator
ParticipantsBF-200 ALAVehicle
Overall — Very Good6711
Overall — Good216
Overall — Satisfactory255
Overall — Unsatisfactory49
By Treatment Area: Extremities — Very Good487
By Treatment Area: Extremities — Good176
By Treatment Area: Extremities — Satisfactory235
By Treatment Area: Extremities — Unsatisfactory46
By Treatment Area: Neck/Trunk — Very Good194
By Treatment Area: Neck/Trunk — Good40
By Treatment Area: Neck/Trunk — Satisfactory20
By Treatment Area: Neck/Trunk — Unsatisfactory03
SecondaryEsthetic Outcome at the End of Treatment Phase Assessed by the Subject

The esthetic outcome after the last PDT as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.

Time frame:
On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Esthetic Outcome at the End of Treatment Phase Assessed by the Subject
ParticipantsBF-200 ALAVehicle
Overall — Very Good537
Overall — Good308
Overall — Satisfactory265
Overall — Unsatisfactory811
By Treatment Area: Extremities — Very Good413
By Treatment Area: Extremities — Good217
By Treatment Area: Extremities — Satisfactory225
By Treatment Area: Extremities — Unsatisfactory89
By Treatment Area: Neck/Trunk — Very Good124
By Treatment Area: Neck/Trunk — Good91
By Treatment Area: Neck/Trunk — Satisfactory40
By Treatment Area: Neck/Trunk — Unsatisfactory02
SecondarySatisfaction With PDT at the End of Treatment Phase

Satisfaction with PDT treatment after the last PDT as assessed by the subject; overall and stratified by treatment area. Therefore, subjects were asked if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no).

Time frame:
On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Satisfaction With PDT at the End of Treatment Phase
ParticipantsBF-200 ALAVehicle
Overall — Subject would choose PDT again10126
Overall — Subject would not choose PDT again164
By Treatment Area: Extremities — Subject would choose PDT again8019
By Treatment Area: Extremities — Subject would not choose PDT again124
By Treatment Area: Neck/Trunk — Subject would choose PDT again217
By Treatment Area: Neck/Trunk — Subject would not choose PDT again40
SecondaryFrequency and Extent of Adverse Events (AEs), AEs of Special Interest (AESIs), Serious AEs (SAEs) and Treatment-emergent AEs (TEAEs) During Treatment Phase

Frequency and extent of AEs, AESIs, SAEs, and TEAEs, overall and stratified by demographics, skin type class (I-III and IV-VI), size of the treatment field, and treatment area. TEAEs were defined as all AEs starting with or after IMP application and within 12 weeks (+ 7 days) after the last PDT, or as related AEs (possibly, probably, or definitely related, or with missing relationship) occurring more than 12 weeks after the last PDT.

Time frame:
During entire treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Reported as:
Count of participants · Participants
Frequency and Extent of Adverse Events (AEs), AEs of Special Interest (AESIs), Serious AEs (SAEs) and Treatment-emergent AEs (TEAEs) During Treatment Phase
ParticipantsBF-200 ALAVehicle
AEs13225
AESIs00
SAEs124
TEAEs13125
TEAEs - By age group: 18 - 64 years415
TEAEs - By age group: 65 - 74 years5715
TEAEs - By age group: 75 years and older335
TEAEs - By sex: female5916
TEAEs - By sex: male729
TEAEs - By Fitzpatrick skin type: Type I - III12623
TEAEs - By Fitzpatrick skin type: Type IV - VI52
TEAEs - By Size of treatment field: 80 cm²345
TEAEs - By Size of treatment field: 160 cm²5012
TEAEs - By Size of treatment field: 240 cm²478
TEAEs - By treatment area: Extremities10518
TEAEs - By treatment area: Neck/trunk267
SecondaryNew Lesions Inside the Treatment Field During Treatment Phase

New lesions: AK, non-melanoma skin cancer \[NMSC, including Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) or Bowen's Disease (BD)\] or melanoma

Time frame:
All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Reported as:
Count of participants · Participants
New Lesions Inside the Treatment Field During Treatment Phase
ParticipantsBF-200 ALAVehicle
New Lesions Inside the Treatment Field During Treatment Phase246
SecondaryAssessment of Application Site Reactions

Application site reactions (bleeding, burning, discharge, edema, erosion, erythema, exfoliation, hyperalgesia, induration, irritation, paraesthesia, pruritus, pustules, scabbing, or vesicles) were assessed on a 4-point scale: grade 0 = none, grade 1 = mild, grade 2 = moderate, grade 3 = severe. The worst severity across all assessment timepoints and illumination areas is presented.

Time frame:
All visits (except screening, Visit 1) throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Reported as:
Count of participants · Participants
Assessment of Application Site Reactions
ParticipantsBF-200 ALAVehicle
Burning — None4130
Burning — Mild474
Burning — Moderate340
Burning — Severe80
Hyperalgesia — None10133
Hyperalgesia — Mild161
Hyperalgesia — Moderate120
Hyperalgesia — Severe10
Irritation — None9532
Irritation — Mild212
Irritation — Moderate110
Irritation — Severe30
Paraesthesia — None8431
Paraesthesia — Mild323
Paraesthesia — Moderate140
Paraesthesia — Severe00
Pruritus — None6927
Pruritus — Mild517
Pruritus — Moderate90
Pruritus — Severe10
Bleeding — None12834
Bleeding — Mild10
Bleeding — Moderate10
Bleeding — Severe00
Discharge — None12834
Discharge — Mild20
Discharge — Moderate00
Discharge — Severe00
Edema — None9732
Edema — Mild242
Edema — Moderate90
Edema — Severe00
Erosion — None11733
Erosion — Mild81
Erosion — Moderate10
Erosion — Severe40
Erythema — None3020
Erythema — Mild4612
Erythema — Moderate422
Erythema — Severe120
Exfoliation — None10233
Exfoliation — Mild191
Exfoliation — Moderate50
Exfoliation — Severe40
Induration — None10534
Induration — Mild170
Induration — Moderate70
Induration — Severe10
Pustules — None12234
Pustules — Mild50
Pustules — Moderate20
Pustules — Severe10
Scabbing — None9633
Scabbing — Mild291
Scabbing — Moderate40
Scabbing — Severe10
Vesicles — None11834
Vesicles — Mild80
Vesicles — Moderate30
Vesicles — Severe10
SecondaryApplication Site Pain During Illumination

Reported by the subjects assessed on an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain); overall and stratified by size of the treatment field and treatment area. The maximum of pain score over all illuminations is shown.

Time frame:
During treatment (illumination) on treatment day for PDT-1 (Visit 2, up to 4 weeks after screening) and during treatment (illumination) on treatment day for PDT-2 (Visit 4; if applicable; 12 weeks after PDT-1)
Reported as:
Mean · Pain score
Application Site Pain During Illumination
Pain scoreBF-200 ALAVehicle
Overall5.4 ± 2.50.4 ± 0.7
By Treatment Area: Extremities5.3 ± 2.40.4 ± 0.7
By Treatment Area: Neck/Trunk5.8 ± 2.70.3 ± 0.5
By Size of the Treatment Field: 80 cm²4.6 ± 2.20.1 ± 0.3
By Size of the Treatment Field: 160 cm²5.1 ± 2.20.4 ± 0.6
By Size of the Treatment Field: 240 cm²6.5 ± 2.60.5 ± 0.9
SecondaryNumber of Patients With Significant Changes of Vital Signs

Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\] and changes in pulse rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Reported as:
Count of participants · Participants
Number of Patients With Significant Changes of Vital Signs
ParticipantsBF-200 ALAVehicle
Befort treatment start — Clinically significant vital signs reported20
Befort treatment start — No clinically significant vital signs reported13436
After treatment start — Clinically significant vital signs reported00
After treatment start — No clinically significant vital signs reported13636
SecondaryNumber of Patients With Significant Changes in Safety Laboratory

Changes in clinical chemistry, in hematology and urinalysis parameters as defined in the protocol. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Reported as:
Count of participants · Participants
Number of Patients With Significant Changes in Safety Laboratory
ParticipantsBF-200 ALAVehicle
Befort treatment start — Clinically significant safety laboratory results reported11
Befort treatment start — No clinically significant safety laboratory results reported13535
After treatment start — Clinically significant safety laboratory results reported10
After treatment start — No clinically significant safety laboratory results reported13536
SecondaryNumber of Patients With Abnormal Findings in Physical Examination

Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.

Time frame:
At screening (up to 4 weeks before treatment) and 12 weeks after the last PDT (Visit 4 or Visit 6)
Reported as:
Count of participants · Participants
Number of Patients With Abnormal Findings in Physical Examination
ParticipantsBF-200 ALAVehicle
Befort treatment start — Clinically significant physical examination findings reported10
Befort treatment start — No clinically significant physical examination findings reported13536
After treatment start — Clinically significant physical examination findings reported10
After treatment start — No clinically significant physical examination findings reported13536

Adverse events

Collected over Collection of AEs started with signing the informed consent documents and ended with the end of the treatment phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BF-200 ALA0/136 (0%)12/136 (8.8%)132/136 (97.1%)
Vehicle0/36 (0%)4/36 (11.1%)24/36 (66.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventBF-200 ALAVehicle
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1361/36
Hiatus herniaGastrointestinal disorders0/1361/36
Pelvic fractureInjury, poisoning and procedural complications0/1361/36
KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1361/36
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1361/36
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1360/36
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1360/36
Coronary artery diseaseCardiac disorders1/1360/36
Staphylococcal skin infectionInfections and infestations1/1360/36
Electrocardiogram abnormalInvestigations1/1360/36
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBF-200 ALAVehicle
Application site erythemaGeneral disorders110/13614/36
Application site painGeneral disorders100/1364/36
Application site pruritusGeneral disorders73/1368/36
Application site paraesthesiaGeneral disorders49/1363/36
Application site exfoliationGeneral disorders38/1361/36
Application site oedemaGeneral disorders38/1362/36
Application site irritationGeneral disorders35/1362/36
Application site scabGeneral disorders34/1361/36
Application site hyperaesthesiaGeneral disorders30/1361/36
Application site indurationGeneral disorders25/1360/36

Baseline characteristics

Participants were randomized to the treatment arms in 4:1 ratio.

Age, Customized
Age, Customized(Participants)BF-200 ALAVehicleTotal
Number of Participants Analyzed — 18 - 64 years411051
Number of Participants Analyzed — 65 - 74 years602181
Number of Participants Analyzed — 75 years and older35540
Sex: Female, Male
Sex: Female, Male(Participants)BF-200 ALAVehicleTotal
Female602080
Male761692
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BF-200 ALAVehicleTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White13636172
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BF-200 ALAVehicleTotal
Hispanic or Latino101
Not Hispanic or Latino13536171
Unknown or Not Reported000
Fitzpatrick Skin Type, Categorical
Fitzpatrick Skin Type, Categorical(Participants)BF-200 ALAVehicleTotal
Type I - III13133164
Type IV - VI538
08

Study locations

14 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Alliance Dermatology & Mohs Center
    Phoenix, Arizona 85032, United States
  • Dermatology Practice
    Greenwood Village, Colorado 80111, United States
  • Dermatology Associates PA of the Palm Beaches
    Delray Beach, Florida 33445, United States
  • Gwinnett Clinical Research Center, Inc.
    Snellville, Georgia 30078, United States
  • Laser and Skin Surgery Center of Indiana
    Indianapolis, Indiana 46260, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • Skin Search of Rochester, Inc.
    Rochester, New York 14623, United States
  • Rochester Dermatologic Surgery
    Victor, New York 14564, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • DermResearch, P.A.
    Austin, Texas 78759, United States
  • Austin Institute for Clinical Research
    Houston, Texas 77056, United States
  • Austin Institute for Clinical Research Inc.
    Pflugerville, Texas 78660, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2025, 32 months.

Results were first posted in Aug 2026, 11 months after primary completion.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 22, 2022
StartActual
Dec 12, 2022
Primary completionActual
Sep 3, 2025
CompletionActual
Jul 1, 2026
Results first posted
Aug 21, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05662202
Lead sponsor
Biofrontera Inc.
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Dec 12, 2022
Primary completion
Sep 3, 2025
Completion
Jul 1, 2026
Results posted
Aug 21, 2026
Last update
Aug 21, 2026

Study contacts

Nathalie Zeitouni, MD
principal investigator · Medical Dermatology Specialists; Phoenix, Arizona, United States

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion